Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug
Vertex Pharmaceuticals (NASDAQ: VRTX) made news last week when its long-anticipated cystic fibrosis treatment, Trikafta, received approval from the U.S. Food and Drug Administration (FDA). While this is good news in and of itself, investors and analysts alike were impressed by the fact that Vertex's Trikafta earned this approval only three months after the application was filed, five months sooner than anticipated.
With this new cystic fibrosis drug now only weeks away from being available in pharmacies across the country, the already bullish appraisal for the biotech stock seems to have become even more optimistic. Let's take a look at what exactly this means for Vertex as well as some considerations investors should keep in mind going forward.
Image source: Getty Images.
Source Fool.com
